Cargando…

Factor Xa Inhibition with Apixaban Does Not Influence Cardiac Remodelling in Rats with Heart Failure After Myocardial Infarction

BACKGROUND: Heart failure (HF) is considered to be a prothrombotic condition and it has been suggested that coagulation factors contribute to maladaptive cardiac remodelling via activation of the protease-activated receptor 1 (PAR1). We tested the hypothesis that anticoagulation with the factor Xa (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yurista, Salva R., Silljé, Herman H. W., Nijholt, Kirsten T., Dokter, Martin M., van Veldhuisen, Dirk J., de Boer, Rudolf A., Westenbrink, B. Daan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452585/ https://www.ncbi.nlm.nih.gov/pubmed/32458320 http://dx.doi.org/10.1007/s10557-020-06999-7

Ejemplares similares

Ketone Ester Treatment Improves Cardiac Function and Reduces Pathologic Remodeling in Preclinical Models of Heart Failure
por: Yurista, Salva R., et al.
Publicado: (2020)

Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes?
por: Yurista, Salva R., et al.
Publicado: (2020)

Effects of Sodium–Glucose Co-transporter 2 Inhibition with Empaglifozin on Renal Structure and Function in Non-diabetic Rats with Left Ventricular Dysfunction After Myocardial Infarction
por: Yurista, Salva R., et al.
Publicado: (2020)

The erythropoietin receptor expressed in skeletal muscle is essential for mitochondrial biogenesis and physiological exercise
por: Nijholt, Kirsten T., et al.
Publicado: (2021)

A Kinase Interacting Protein 1 (AKIP1) promotes cardiomyocyte elongation and physiological cardiac remodelling
por: Nijholt, Kirsten T., et al.
Publicado: (2023)

Mitochondrial therapy for doxorubicin cardiomyopathy: nuclear factor-κB to the rescue?
por: Nijholt, Kirsten Theresa, et al.
Publicado: (2020)

The new factor Xa inhibitor: Apixaban
por: Bhanwra, Sangeeta, et al.
Publicado: (2014)

SGLT2 Inhibitors and Ketone Metabolism in Heart Failure
por: Saucedo-Orozco, Huitzilihuitl, et al.
Publicado: (2022)

ATPase Inhibitory Factor-1 Disrupts Mitochondrial Ca(2+) Handling and Promotes Pathological Cardiac Hypertrophy through CaMKIIδ
por: Pavez-Giani, Mario G., et al.
Publicado: (2021)

Exercise: a molecular tool to boost muscle growth and mitochondrial performance in heart failure?
por: Nijholt, Kirsten T., et al.
Publicado: (2022)

Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum
por: Siddiqui, Fakiha, et al.
Publicado: (2019)

From Inflammation to Fibrosis—Molecular and Cellular Mechanisms of Myocardial Tissue Remodelling and Perspectives on Differential Treatment Opportunities
por: Suthahar, Navin, et al.
Publicado: (2017)

Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
por: Upreti, Vijay V, et al.
Publicado: (2013)

A Kinase Interacting Protein 1 regulates mitochondrial protein levels in energy metabolism and promotes mitochondrial turnover after exercise
por: Nijholt, Kirsten T., et al.
Publicado: (2023)

Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor
por: Wong, Pancras C., et al.
Publicado: (2011)

Short-Chain Fatty Acids in the Metabolism of Heart Failure – Rethinking the Fat Stigma
por: Palm, Constantin L., et al.
Publicado: (2022)

AKIP1, a Cardiac Hypertrophy Induced Protein that Stimulates Cardiomyocyte Growth via the Akt Pathway
por: Yu, Hongjuan, et al.
Publicado: (2013)

Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure
por: Yin, Meimei, et al.
Publicado: (2011)

The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction
por: Withaar, Coenraad, et al.
Publicado: (2020)

Connecting epicardial adipose tissue and heart failure with preserved ejection fraction: mechanisms, management and modern perspectives
por: van Woerden, Gijs, et al.
Publicado: (2022)

DOACs in Valvular Heart Disease: Latest Key Updates on PROACT Xa (Apixaban) and INVICTUS (Rivaroxaban)
por: Ryu, Rachel
Publicado: (2022)

A universal anti‐Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation
por: Willekens, Guido, et al.
Publicado: (2021)

Galectin-3 in Cardiac Remodeling and Heart Failure
por: de Boer, Rudolf A., et al.
Publicado: (2010)

Regulation of the (pro)renin–renin receptor in cardiac remodelling
por: Mahmud, Hasan, et al.
Publicado: (2012)

Apixaban and rivaroxaban anti-Xa level utilization and associated bleeding events within an academic health system
por: Jakowenko, Nicholas, et al.
Publicado: (2020)

Assessment of Anti‐Xa activity in patients receiving concomitant apixaban with strong p‐glycoprotein inhibitors and statins
por: Milner, Erin, et al.
Publicado: (2022)

Erratum to: Galectin-3 in Cardiac Remodeling and Heart Failure
por: de Boer, Rudolf A., et al.
Publicado: (2012)

AKIP1 Expression Modulates Mitochondrial Function in Rat Neonatal Cardiomyocytes
por: Yu, Hongjuan, et al.
Publicado: (2013)

Dissolution of an apical thrombus by apixaban in a patient with old anteroseptal myocardial infarction
por: Yanıkoğlu, Atakan, et al.
Publicado: (2016)

Predictors of left ventricular remodeling after ST-elevation myocardial infarction
por: Hendriks, Tom, et al.
Publicado: (2017)

Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
por: Frost, Charles, et al.
Publicado: (2013)

Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillation
por: Ikeda, Kozue, et al.
Publicado: (2016)

Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series
por: Schultz, Nina Haagenrud, et al.
Publicado: (2018)

Anti-Xa Inhibitor-Induced Hemorrhagic Pruritic Rash: A Case Report on Possible Cross-Reactivity Between Apixaban and Rivaroxaban
por: Anis, Takla R, et al.
Publicado: (2021)

Usefullness of Heparin Calibrated Anti-Xa Activity to Assess Anticoagulant Activity of Apixaban and Rivaroxaban in Emergency Patients Scheduled for Acute Interventions
por: Riahi, Nada, et al.
Publicado: (2023)

Accuracy of a Single, Heparin-Calibrated Anti-Xa Assay for the Measurement of Rivaroxaban, Apixaban, and Edoxaban Drug Concentrations: A Prospective Cross-Sectional Study
por: Meihandoest, Tamana, et al.
Publicado: (2022)

Predictors of adverse diastolic remodeling in non-diabetic patients presenting with ST-elevation myocardial infarction
por: Al Ali, Lawien, et al.
Publicado: (2023)

Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors
por: Verhoef, Daniël, et al.
Publicado: (2017)

Heart failure-associated anemia: bone marrow dysfunction and response to erythropoietin
por: Ruifrok, Willem-Peter T., et al.
Publicado: (2010)

Left atrial volume and left ventricular mass indices in heart failure with preserved and reduced ejection fraction
por: Gehlken, Carolin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a44qcvalctglod8lkhdudcisrl